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Alberto Briganti5, Francesco Montorsi5,6 and Liang Cheng7Abstract
Background: There is a worldwide debate involving clinicians, uropathologists as well as patients and their families
on whether Gleason score 6 adenocarcinoma should be labelled as cancer.
Case description: We report a case of man diagnosed with biopsy Gleason score 6 acinar adenocarcinoma and
classified as low risk (based on a PSA of 5 ng/mL and stage cT2a) whose radical prostatectomy specimen initially
showed organ confined Gleason score 3 + 3 = 6, WHO nuclear grade 3, acinar adenocarcinoma with lymphovascular
invasion and secondary deposit in a periprostatic lymph node. When deeper sections were cut to the point that
almost all the slice present in the paraffin block was sectioned, a small tumor area (<5% of the whole tumor) of
Gleason pattern 4 (poorly formed glands) was found in an extraprostatic position.
Conclusion: The epilogue was that the additional finding changed the final Gleason score to 3 + 3 = 6 with tertiary
pattern 4 and the stage to pT3a.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/13000_2014_190
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There is a worldwide debate involving clinicians, uropathol-
ogists as well as patients and their families on whether
Gleason score 6 adenocarcinoma should be labelled as can-
cer. There are those in favor of continuing to call it cancer,
while others are in favor of removing the label of cancer
from Gleason 6 tumors [1-5]. Such hot debate is based on
both clinical data and personal view.
Those who speak in favor of leaving the label of cancer
base their opinion on the fact that Gleason score 6 cancer
is composed of Gleason pattern 3 cancer, which shares
cytological and molecular alterations associated with higher
Gleason patterns and has the ability to extend locally* Correspondence: r.montironi@univpm.it
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unless otherwise stated.beyond the prostate and metastasize [2]. Those who speak
in favor of removing such label base their orientation on
data demonstrating that using a time horizon of 10 to
15 years, less than 3% of men diagnosed with Gleason
score 6 and classified as low risk will die as a result of
prostate cancer whether treated or not [6]. A recent paper
by Ross et al. showed that all adenocarcinomas of the
prostate with Gleason Score ≤6 with lymph node me-
tastasis had a higher grade component on slide review
[7]. Finley et al. reported that one lymph node metastasis
within the periprostatic fat was detected in a patient who
had been preoperatively classified as low risk [8].
We report a case of man diagnosed with low risk Gleason
score 6 acinar adenocarcinoma whose radical prostatec-
tomy specimen was reported to harbor Gleason score 6
adenocarcinoma with lymphovascular invasion and metas-
tasis in a periprostatic lymph node. The case presentationral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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behavior.
Case presentation
The patient, 67 years old, had a past 5-year history of in-
creasing urinary obstructive symptoms and clinical diag-
nosis of benign prostatic enlargement for which he had
been treated with an alpha(1A)/alpha(1D)-adrenoceptor
antagonist. There was no history of other medications or
hormonally-active supplements. No comorbidities, includ-
ing diabetes, were present.
His most recent preoperative total serum PSA was
7.2 ng/ml, with a free-to-total ratio of 0.12. Transrectal
ultrasound revealed a hypoechoic area in the left mid
part of the prostate. Induration of the same prostate
zone was detected by digital rectal examination. Twelve
random ultrasound guided prostatic needle cores were
taken. Histological diagnosis of Gleason score 3 + 3 = 6
acinar adenocarcinoma occupying 40% of one of the 12
cores, from the left part of the prostate and correspond-
ing to the location of the hypoechoic area, was made.
The tumor was classified in the low risk category. Even
though the patient was considered a potential candidate
for active surveillance, open radical prostatectomy (mono-
lateral nerve sparing in the right side) was performed.
Pelvic lymph node dissection was not carried out.
The prostate specimen was received fresh from the op-
erating room. Its weight without the seminal vesicles (33
grams) and all three dimensions were recorded, the latterFigure 1 Whole mount section. The dominant nodule, contained in the
thin bleu arrow) and lymphovascular invasion (insert B; thin green arrow). T
arrow) with metastasis (light pink part of the lymph node).used for prostate volume calculation (24.12 cc). The speci-
men was then covered with India ink and fixed for
48 hours in 4% neutral buffered formalin. After fixation,
the apex and base (3 mm thick slices) were removed from
each specimen and examined by the cone method. The
prostate body was step-sectioned at 3 mm intervals per-
pendicular to the long axis of the gland. The seminal vesi-
cles were cut into two halves and processed in toto. The
cut specimen was post-fixed and then dehydrated in
graded alcohols, cleared in xylene, embedded in paraffin
and examined histologically as 5 μm-thick whole-mount
hematoxylin and eosin (H&E) stained sections. The
Gleason grading was based on the 2010 modification of
the “2005 ISUP Modified Gleason System” [9]. Staging was
done according to the 2009 TNM revision [10].
The histological examination of the prostate showed a
dominant nodule located in the peripheral zone, postero-
lateraly in the left mid portion of the prostate body
(Figure 1). The nodule, 1.3 cm in greatest diameter
(volume 0.7 cc), showed the following features: acinar
adenocarcinoma (Figure 1A), Gleason score 3 + 3 = 6,
WHO nuclear grade 3, negative surgical margin, no extra-
prostatic extension, even though the tumor reached the
so-called prostate capsule, and lymphovascular invasion in
the parenchyma adjacent to the tumor (Figure 1B). The
left posterolateral periprostatic adipose tissue, adjacent to
the prostate dominant cancer nodule, contained a lymph
node, 0.5 cm in greatest diameter, with a secondary de-
posit of Gleason 6 adenocarcinoma (diameter 0.3 cm)circled area, with acinar adenocarcinoma Gleason score 6 (Insert A;
he adjacent periprostatic fat tissue shows a lymph node (thick red
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present in the right lateral horn with the features of an in-
significant: Gleason score 3 + 3 = 6 acinar adenocarcinoma,
3 mm in diameter (volume 0.1 cc), with negative surgical
margin and no extraprostatic extension (Stage pT2c) (See
the Conclusions Paragraph).
Discussion
The tumor was initially characterized by the following
main features: Gleason score 3 + 3 = 6, WHO grade 3,
lymphovascular invasion, and a lymph node with metas-
tasis in the periprostatic soft tissue.
In our current presentation, the index tumor consisted
of variably sized individual well-formed gland, without
cribriform glands, individual cells and glomeruloid fea-
tures, i.e., Gleason score 3 + 3 = 6. The same score was
observed in the biopsy, dominant nodule of the specimen
and lymph node deposit. The Gleason grading system of
prostatic carcinoma is the quintessential prognostic factor
in predicting findings in radical prostatectomy, biochem-
ical failure, local recurrences, lymph node or distant metas-
tasis in patients receiving no treatment, radiation therapy,
radical prostatectomy and other therapies, including cryo-
therapy and high intensity focal ultrasound therapy
[9,11-13]. Clinicians use routinely various tools, such as
Partin tables or Kattan nomograms, to predict outcomes,
including pathological stage or prognosis following treat-
ment [14,15]. All of these tools incorporate the Gleason
score.
The International Society of Urological Pathology con-
vened a conference in 2005 in San Antonio, TX, USA, in
an attempt to achieve consensus in controversial areas
relating to the Gleason system. This has led to what is
called “2005 ISUP Modified Gleason System” [12]. Lesions
previously referred to as Gleason scores 2 to 4 in the clas-
sic system are now assigned a higher grade (Gleason score
6) in the modified system; however, those previously
graded as Gleason score 6 in the classic system are often
graded as Gleason score 7 tumors in the modified system.
It has recently been recommended by Dr JI Epstein that
all cribriform patterns are diagnosed as Gleason pattern 4
rather than pattern 3. It has also been suggests that glo-
merulations most likely represent an early stage of cribri-
form pattern 4 cancer and should likely be graded as
pattern 4. Such recent changes are also known as 2010
modification of the “2005 ISUP Modified Gleason System”
[9]. The general theme of such changes was to limit the
definition of pattern 3 carcinoma and widen the scope of
pattern 4 carcinoma.
The Gleason system and its revisions are based on the
architectural patterns of PCa. The contribution of nu-
clear morphology to its further refinement has been inves-
tigated only to a limited extent. It is worth mentioning the
proposal made by Mostofi in 1999 in a WHO-sponsoredmeeting in Paris, France, to supplement the Gleason
system with the WHO nuclear grading scheme [16].
The proposal was based on his and his group’s (in
particular, Dr Isabel Sesterhenn’s) experience that pa-
tients with a Gleason score of 6 or higher cancers can be
stratified based on the WHO nuclear grading and that
such stratification has prognostic importance. As shown
in the Figure 2, patients with Gleason score 6 and WHO
nuclear grade 3 had significant higher cancer specific mor-
tality than those with lower grades. This was recently con-
fined in a morphometric study in which it was shown that
the nuclear signature is important to better define risk
groups in PCa patients [17]. In our current case the WHO
grade was 3. Based on the findings of the present case, it
is suggested that, in those patients who meet the current
criteria for active surveillance, the tumor should also be
evaluated for the presence of a WHO grade. If this finding
is observed, the patient should be further evaluated for the
presence of additional prognostic factors that can better
define the aggressiveness of the lesion and require imme-
diate therapy.
Our case showed LVI in the peritumoral parenchyma.
LVI has been defined as the unequivocal presence of
tumor cells within endothelial-lined spaces with no
underlying muscular walls or as the presence of tumor
emboli in small intraprostatic vessels. Baydar et al. [18]
classified lymphovascular invasion as intratumoral
(55%), at the periphery of the tumor (18%), both intra-
and peritumoral (9%), and at a distant site from the tumor
(18%). Univariate analyses showed lymphovascular inva-
sion to be a significant predictor of disease recurrence
and/or progression following radical prostatectomy and
multivariate analyses have confirmed that lymphovascular
invasion is an independent predictor of disease recurrence,
when controlling for other pathologic variables known
to influence clinical outcome. Studies have demonstrated
an association between the presence of lymphovascular in-
vasion and decreased time to biochemical progression,
distant metastases, and overall survival after radical pros-
tatectomy [18-20].
Our case showed metastasis in a periprostatic lymph
node, i.e., in the periprostatic fat and in areas outside the
standard lymphadenectomy. There are very few studies on
the incidence and location of periprostatic/periseminal
vesicle (PP/PSV) lymph nodes and the frequency of their
involvement by metastatic PCa. In the study by Kothari
et al. [21] 4.4% of patients showed PP/PSV lymph nodes.
Sizes ranged from 0.7 to 4.5 mm (mean 1.8 mm). Distribu-
tion was 2 of 39 (5.1%) apical, 3 of 39 (7.7%) mid, 17 of 39
(43.6%) base, and 17 of 39 (43.6%) seminal vesicle. 0.6%
had metastatic PCa to the PP/PSV lymph nodes. A recent
study by Hansen et al. [22] found lymph nodes within
periprostatic fat pads were detected in 5.5% patients,
i.e., 19 patients. Metastasis was found in 4, only one
Figure 2 This is a reproduction of the original diagram given by Dr Mostofi to one of the authors (RM). Patients with Gleason score
(i.e., Gleason sum) 6 and WHO high or marked nuclear grade have higher cancer of the prostate (CAP) death rate than those with lower grades
(slight and moderate).
Figure 3 Small tumor area (<5% of the whole tumor) of Gleason
pattern 4 (poorly formed glands) in an extraprostatic position.
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3 being pT3. Finley et al. reported that one lymph node
metastasis within the periprostatic fat was detected in a
patient who had been preoperatively classified as low risk,
similar to our case [8]. These findings implicate that pa-
tients who seem to have low-risk PCa may harbor PCa
metastases within lymph nodes of the periprostatic fat
even if they do not have positive pelvic lymph nodes. Von
Bodman et al and Briganti et al reported that the number
of positive lymph nodes affects prognosis in PCa patients
with lymph node metastases and reported cut-offs of 1
and 2 positive lymph nodes associated with adverse
disease-related outcomes, respectively [23,24]. In this con-
text, one positive lymph node within the periprostatic fat
pad may influence a patient’s prognosis [22] and should be
reported as N1 according to the AJCC Cancer Staging
Manual [21].
Conclusions
When the paper based on the current case was consid-
ered ready for submission, we thought about a possible
comment from a reader: Was the paraffin block contain-
ing the prostate slice with the dominant nodule and the
lymph node serially sectioned to see whether the lesion
changed in deeper sections? To give an answer to this
possible question, deeper sections were cut to the point
that almost all the slice was sectioned. We found a small
tumor area (<5% of the whole tumor) of Gleason pattern
4 (poorly formed glands) in an extraprostatic position
(Figure 3). This changed our final Gleason score to 3 + 3 =
6 with tertiary pattern 4 and the stage from pT2c to pT3a.This lead us to acquire some information on the follow-up
of the patient whose radical prostatectomy was done in
2005. He is under complete androgen blockade therapy for
a postoperative rising PSA levels and pelvic lymph node
metastasis.
Our morphologic findings of Gleason score to 3 + 3 =
6 with tertiary pattern 4 with lymph node metastasis are
in agreement with the histological observation made by
Ross et al. [7]. They reviewed the slides of 17 radical pros-
tatectomy specimens with Gleason Score (GS) ≤6 cancer
and pelvic lymph node metastases. They found that 2 of
their cases had tertiary pattern 4 with small cribriform
glands. However, it was unknown whether it was the ter-
tiary pattern 4 to confer the metastatic potential to the
disease. An answer to this was given by Haffner et al. [25]
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cing and molecular pathological analyses to characterize
the lethal cell clone in a patient who died of prostate can-
cer. They tracked the evolution of the lethal cell clone
from the primary cancer to metastases through samples
collected during disease progression and at the time of
death. Surprisingly, these analyses revealed that the lethal
clone arose from a small Gleason pattern 3 cancer focus
in the primary tumor, and not from the bulk, higher-grade
primary cancer or from a lymph node metastasis resected
at prostatectomy.
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